NL-OMON24401已完成不适用
BIO-SWITCH study: Biosimilar of Infliximab Options, Strengths and Weaknesses of Infliximab Treatment CHange
Participating hospitals are:Sint Maartenskliniek NijmegenMaartenskliniek WoerdenRadboud University Medical Centre NijmegenRijnstate Arnhem0 个研究点目标入组 200 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 200
研究概览
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1. A clinical diagnosis of either RA, SpA or PsA.
- •2. Currently being treated with Remicade (1 or more infusions)
- •3. > 18 years of age
- •4. Ability to read and communicate well in Dutch
- •5. Informed consent
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
The effects of switching one drug, used to treat either Ulcerative Colitis (UC) or Crohn’s disease (CD) to another drug, also used to treat UC or Crohn’s diseaseEUCTR2018-001546-33-GBniversity Southampton Hospital NHS Foundation Trust200
Unknown
4 期
"Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial"Colitis, UlcerativeCrohn's DiseaseNCT02452151Onze Lieve Vrouwe Gasthuis300
已完成
早期 1 期
Efficacy and Safety of Infliximab Biosimilar in the Treatment of Resistant Hidradenitis SuppurativaHidradenitis SuppurativaNCT05663268Services Institute of Medical Sciences, Pakistan37
已完成
3 期
A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE)Rheumatoid ArthritisNCT02990806Nichi-Iko Pharmaceutical Co., Ltd.683
已完成
不适用
Efficacy and safety of the biosimilar Infliximab in the patients with ulcerative colitisulcerative colitisJPRN-UMIN000027465niversity of Toyama20